Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19665125 | 0.92 | TP53 (0.30) | MAPTTP53 | |
| SCHEMBL19665143 | 0.92 | TP53 (0.30) | MAPTTP53 | |
| SCHEMBL19665124 | 0.92 | TP53 (0.30) | MAPTTP53 | |
| SCHEMBL19665145 | 0.92 | TP53 (0.30) | MAPTTP53 | |
| SCHEMBL19665126 | 0.92 | TP53 (0.30) | MAPTTP53 | |
| SCHEMBL20424623 | 0.90 | — | — | |
| SCHEMBL17871799 | 0.87 | GAA (0.35) | MAPTALDH1A1GAANPSR1KMT2A | |
| SCHEMBL20424427 | 0.82 | KMT2A (0.38) | MAPTALDH1A1GAAKMT2ALMNA | |
| SCHEMBL20424833 | 0.81 | CSF1R (0.31) | KMT2AMEN1 | |
| SCHEMBL26005425 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573972-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2026-01-14 | — | — | EP | disclosed |
| US-11077115-B2 | Rorgamma modulators and uses thereof | GENFIT (FR) | 2021-08-03 | — | — | US | disclosed |
| WO-2018138359-A1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077115-B2 | Rorgamma modulators and uses thereof | RORB, RORC, RORA | MAPT 4111/4885ALDH1A1 761/4885MCOLN3 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.